This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Heart failure affects an estimated 64.3 million people worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Expands bioprocessing footprint across Asia
While Merck can appeal, Halozyme said it expects the order to hold
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Subscribe To Our Newsletter & Stay Updated
